A phase I, two-part, randomized, double-blind, placebo controlled, dose-escalation study designed to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of VTX2735 in adult healthy volunteers
Latest Information Update: 12 May 2023
At a glance
- Drugs VTX 2735 (Primary)
- Indications Inflammation
- Focus Adverse reactions
- Sponsors Ventyx Biosciences
- 21 Mar 2023 Status changed from recruiting to completed.
- 21 Mar 2023 Results assessing Pharmacokinetics, Safety and Pharmacodynamics of VTX2735, In Healthy Adult Volunteers presented at the American Academy of Dermatology annual Meeting 2023
- 29 Jun 2022 Results presented in a Ventyx Biosciences media release.